Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MANGALAM

MAN DRUGORG

HealthcarePharmaceuticals & Biotechnology₹45 cr market cap
₹28.42 ▲ +0.11% today As of 19 Nov 2026
52-week low ₹23.7852-week high ₹62.58

-54.6% from the 52-week high · +19.4% above the low

Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra and currently employs 523 full-time employees. The company went IPO on 2005-05-26. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. The company also focuses on specialty chemicals. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.

The short version. MAN DRUGORG reported revenue of ₹79 crore for Sep 2026, up 58.0% from a year earlier. Net profit was ₹-7 crore. Return on equity was -43.1% in Mar 2026. Promoter holding was 35.65% in Sep 2026, down 14.65 points over 8 quarters.

1 · The price

How has the stock traded?

MAN DRUGORG trades 54.6% below its 52-week high and 19.4% above its 52-week low.

Change over period: —

1M-7.0%
3M+5.4%
6M-7.7%
1Y-53.6%

2 · The business

Is it growing?

Sales, year on year+58.0%

Sep 2026 revenue of ₹79 cr.

Net margin-9.1%

5.7 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7957675850577389
Net profit-7-8-13-10-7-1401
Net margin %-9.1-13.4-19.9-16.8-14.8-24.10.11.5
EPS (₹)-4.55-4.83-8.48-6.21-4.64-8.720.040.81

Annual

FY2026FY2025FY2024
Revenue232318369
Net profit-447-9
Net margin %-19.12.1-2.5
EPS (₹)-28.054.25-5.73

3 · The quality

How well does it turn capital into profit?

Return on equity was -43.1% in Mar 2026; debt to equity is 1.02.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %-43.14.5-6.7—
Return on capital %-27.311.31.7—
EBITDA margin %-6.111.44.8—
Net margin %-19.12.1-2.5—

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity1.02
Interest cover-2.0x
Current ratio0.79

4 · The owners

Who holds it, and are they adding?

Promoter holding35.65%

Down 14.65 pts over 8 quarters.

Foreign institutions0.11%

Unchanged over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.350.350.350.335.6435.6535.6535.65-14.65
FII0.110.470.530.110.130.320.110.110.0
DII000000000
Public49.5849.2349.1649.5864.2264.0264.2464.24+14.66

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MAN DRUGORG are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MAN DRUGORG

What is the MAN DRUGORG share price?

MAN DRUGORG (MANGALAM) last closed at ₹28.42, up 0.11% on the day. Its 52-week range is ₹23.78 to ₹62.58.

What is the market cap of MAN DRUGORG?

MAN DRUGORG has a market capitalisation of about ₹45 crore.

How are MAN DRUGORG's latest results?

MAN DRUGORG reported revenue of ₹79 crore for Sep 2026, up 58.0% from a year earlier. Net profit was ₹-7 crore. Return on equity was -43.1% in Mar 2026. Promoter holding was 35.65% in Sep 2026, down 14.65 points over 8 quarters.

Who owns MAN DRUGORG?

As of Sep 2026, shareholding was: Promoter 35.65%, FII 0.11%, Public 64.24%.

How many mutual funds hold MAN DRUGORG?

0 mutual fund schemes held MAN DRUGORG in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 21 Dec 2017 · Interim Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.